litlas
Log inCreate account

Nigel H. Greig

Active 1984–2026

180
Papers
24,359
Citations
87
h-index
171
i10-index

Citations

Citations per year for Nigel H. Greig1986: 2 citations1987: 3 citations1988: 2 citations1989: 6 citations1990: 7 citations1991: 6 citations1992: 10 citations1993: 5 citations1994: 6 citations1995: 4 citations1996: 9 citations1997: 9 citations1998: 12 citations1999: 19 citations2000: 22 citations2001: 44 citations2002: 91 citations2003: 130 citations2004: 130 citations2005: 135 citations2006: 173 citations2007: 130 citations2008: 158 citations2009: 164 citations2010: 204 citations2011: 259 citations2012: 322 citations2013: 259 citations2014: 262 citations2015: 221 citations2016: 219 citations2017: 266 citations2018: 300 citations2019: 984 citations2020: 1,149 citations2021: 1,156 citations2022: 1,127 citations2023: 820 citations2024: 1,304 citations2025: 864 citations2026: 38 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,507 citing papers, 20.5% of this breakdownChina: 1,800 citing papers, 14.7% of this breakdownIndia: 622 citing papers, 5.1% of this breakdownUnited Kingdom: 610 citing papers, 5% of this breakdownItaly: 540 citing papers, 4.4% of this breakdownGermany: 403 citing papers, 3.3% of this breakdownCanada: 389 citing papers, 3.2% of this breakdownAustralia: 302 citing papers, 2.4% of this breakdownSouth Korea: 299 citing papers, 2.4% of this breakdownSpain: 290 citing papers, 2.4% of this breakdownFrance: 255 citing papers, 2.1% of this breakdownSaudi Arabia: 215 citing papers, 1.7% of this breakdown
0%20.5%Other 32.8%

Institutions

Fields

  • Medicine59.6%
  • Biochemistry, Genetics and Molecular Biology17.2%
  • Neuroscience13.2%
  • Computer Science2.5%
  • Nursing1.4%
  • Agricultural and Biological Sciences1.3%
  • Other4.8%

Topics

  • Alzheimer's disease research and treatments8.2%
  • Cholinesterase and Neurodegenerative Diseases6.3%
  • Computational Drug Discovery Methods4.8%
  • Neuroinflammation and Neurodegeneration Mechanisms4%
  • Diabetes Treatment and Management3%
  • Parkinson's Disease Mechanisms and Treatments2.9%
  • Other70.8%

Coauthors

All papers

Open in search
  1. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

    Authors: Evandro Fei Fang, Yujun Hou, Konstantinos Palikaras, Bryan A. Adriaanse, Jesse S. Kerr, Beimeng Yang, Sofie Lautrup, Md Mahdi Hasan‐Olive, Domenica Caponio, Xiuli Dan, Paula Rocktäschel, Deborah L. Croteau, Mansour Akbari, Nigel H. Greig, Tormod Fladby, Hilde Nilsen, M. Zameel Cader, Mark P. Mattson, Nektarios Tavernarakis, Vilhelm A. Bohr - Nature Neuroscience 2019 cited by 1,696

  2. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

    Authors: Dilan Athauda, Kate Maclagan, Simon S. Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Icíar Avilés-Olmos, Thomas T. Warner, Patricia Limousin, Andrew J. Lees, Nigel H. Greig, Susan Tebbs, Thomas Foltynie - The Lancet 2017 cited by 851

  3. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms

    Authors: Jesse S. Kerr, Bryan A. Adriaanse, Nigel H. Greig, Mark P. Mattson, M. Zameel Cader, Vilhelm A. Bohr, Evandro Fei Fang - Trends in Neurosciences 2017 cited by 872

  4. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

    Authors: Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, Nigel H. Greig - Pharmacological Research 2022 cited by 254

  5. Drug discovery and development: Role of basic biological research

    Authors: Richard C. Mohs, Nigel H. Greig - Alzheimer s & Dementia Translational Research & Clinical Interventions 2017 cited by 679

  6. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis

    Authors: Daniela Lecca, Yoo Jin Jung, Michael T. Scerba, Inho Hwang, Yu Kyung Kim, Sun Kim, Sydney Modrow, David Tweedie, Shih‐Chang Hsueh, Dong Liu, Weiming Luo, Elliot J. Glotfelty, Yazhou Li, Jia‐Yi Wang, Yu Luo, Barry J. Hoffer, Dong Seok Kim, Ross A. McDevitt, Nigel H. Greig - Alzheimer s & Dementia 2022 cited by 211

  7. Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function

    Authors: Hyo Youl Moon, Andreas Becke, David Berron, Benjamin Becker, Nirnath Sah, Galit Benoni, Emma Janke, Susan T. Lubejko, Nigel H. Greig, Julie A. Mattison, Emrah Düzel, Henriette van Praag - Cell Metabolism 2016 cited by 617

  8. Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus

    Authors: Gohar Mushtaq, Nigel H. Greig, Jalaluddin A. Khan, Mohammad Amjad Kamal - CNS & Neurological Disorders - Drug Targets 2014 cited by 317

  9. A Pilot Study of Exenatide Actions in Alzheimer’s Disease

    Authors: Roger J. Mullins, Maja Mustapić, Chee W. Chia, Olga D. Carlson, Seema Gulyani, Joyce Tran, Yazhou Li, Mark P. Mattson, Susan M. Resnick, Josephine M. Egan, Nigel H. Greig, Dimitrios Kapogiannis - Current Alzheimer Research 2019 cited by 149

  10. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

    Authors: Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati, Yazhou Li, David Tweedie, Maja Mustapić, Sahil Chawla, Kashfia Chowdhury, Simon S. Skene, Nigel H. Greig, Dimitrios Kapogiannis, Thomas Foltynie - JAMA Neurology 2019 cited by 256

  11. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

    Authors: James Mitchell, Hannah Lyons, Jessica Walker, Andreas Yiangou, Olivia Grech, Zerin Alimajstorovic, Nigel H. Greig, Yazhou Li, Georgios Tsermoulas, Kristian Brock, Susan P. Mollan, Alexandra J. Sinclair - Brain 2023 cited by 145

  12. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

    Authors: Nigel H. Greig, Tadanobu Utsuki, Donald K. Ingram, Yue Wang, Giancarlo Pepeu, Carla Scali, Qian-sheng Yu, Jacek Mamczarz, Harold W. Holloway, Tony Giordano, De‐Mao Chen, Katsutoshi Furukawa, Kumar Sambamurti, Arnold Brossi, Debomoy K. Lahiri - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 723

  13. N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease

    Authors: David Olivares, Varun K. Deshpande, Ying Shi, Debomoy K. Lahiri, Nigel H. Greig, Jack T. Rogers, Xudong Huang - Current Alzheimer Research 2012 cited by 393

  14. Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

    Authors: Isidro Salcedo, David Tweedie, Yazhou Li, Nigel H. Greig - British Journal of Pharmacology 2012 cited by 259

  15. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

    Authors: Nirosen Vijiaratnam, Christine Girges, Grace Auld, Rachel McComish, Alexa King, Simon S. Skene, Steve Hibbert, Alan Wong, Sabina Melander, Rachel Gibson, Helen Matthews, John Dickson, Camille Carroll, Abigail Patrick, Jemma Inches, Monty Silverdale, Bethan Blackledge, Jessica Whiston, Michele Hu, Jessica Welch, Gordon W. Duncan, Katie Power, Sarah Gallen, Jacqueline Kerr, К. Ray Chaudhuri, Lucia Batzu, Silvia Rota, Edwin Jabbari, Huw R. Morris, Patricia Limousin, Nigel H. Greig, Yazhou Li, Vincenzo Libri, Sonia Gandhi, Dilan Athauda, Kashfia Chowdhury, Tom Foltynie - The Lancet 2025 cited by 121

  16. Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

    Authors: TracyAnn Perry, Norman J. Haughey, Mark P. Mattson, Josephine M. Egan, Nigel H. Greig - Journal of Pharmacology and Experimental Therapeutics 2002 cited by 374

  17. An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript

    Authors: Jack T. Rogers, Jeffrey Randall, Catherine M. Cahill, Paul S. Eder, Xudong Huang, Hiromi Gunshin, Lorene M. Leiter, Jay A. McPhee, Satinder S. Sarang, Tada Utsuki, Nigel H. Greig, Debomoy K. Lahiri, Rudolph E. Tanzi, Ashley I. Bush, Tony Giordano, S. R. Gullans - Journal of Biological Chemistry 2002 cited by 546

  18. Butyrylcholinesterase: An Important New Target in Alzheimer’s Disease Therapy

    Authors: Nigel H. Greig, Debomoy K. Lahiri, Kumar Sambamurti - International Psychogeriatrics 2002 cited by 456

  19. GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

    Authors: Yazhou Li, Kara B. Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A. Bailey, Harold W. Holloway, David Tweedie, TracyAnn Perry, Mark P. Mattson, Dimitrios Kapogiannis, Kumar Sambamurti, Debomoy K. Lahiri, Nigel H. Greig - Journal of Alzheimer s Disease 2010 cited by 324

  20. Protein Misfolding and Aggregation in Alzheimer’s Disease and Type 2 Diabetes Mellitus

    Authors: Ghulam Md Ashraf, Nigel H. Greig, Taqi Ahmed Khan, Iftekhar Hassan, Shams Tabrez, Shazi Shakil, Ishfaq A. Sheikh, Syed Kashif Zaidi, Mohammad Akram, Nasimudeen R. Jabir, Chelaprom Firoz, Aabgeena Naeem, Ibrahim M. Alhazza, Ghazi Damanhouri, Mohammad Amjad Kamal - CNS & Neurological Disorders - Drug Targets 2014 cited by 238

  21. Inhibition of Caspase 3 and Caspase 9 Mediated Apoptosis: A MultimodalTherapeutic Target in Traumatic Brain Injury

    Authors: Aziz Unnisa, Nigel H. Greig, Mohammad Amjad Kamal - Current Neuropharmacology 2022 cited by 125

  22. The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia

    Authors: Elliot J. Glotfelty, Luis B. Tovar‐y‐Romo, Shih‐Chang Hsueh, David Tweedie, Yazhou Li, Brandon K. Harvey, Barry J. Hoffer, Tobias E. Karlsson, Lars Olson, Nigel H. Greig - Cells 2023 cited by 53

  23. A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells

    Authors: TracyAnn Perry, Debomoy K. Lahiri, De‐Mao Chen, Jie Zhou, Karen T. Y. Shaw, Josephine M. Egan, Nigel H. Greig - Journal of Pharmacology and Experimental Therapeutics 2002 cited by 298

  24. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments

    Authors: Yoo Jin Jung, David Tweedie, Michael T. Scerba, Nigel H. Greig - Frontiers in Cell and Developmental Biology 2019 cited by 148